Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans

Human plasma contains several catechols, including the catecholamines norepinephrine, epinephrine, and dopamine, their precursor, l-3,4-dihydroxyphenylalanine (l-DOPA), and their deaminated metabolites, dihydroxyphenylglycol, the main neuronal metabolite of norepinephrine, and dihydroxyphenylacetic acid, a deaminated metabolite of dopamine. Products of metabolism of catechols include 3-methoxytyrosine (from l-DOPA), homovanillic acid and dopamine sulfate (from dopamine), normetanephrine, vanillylmandelic acid, and methoxyhydroxyphenylglycol (from norepinephrine), and metanephrine (from epinephrine). Plasma levels of catechols and their metabolites have related but distinct sources and therefore reflect different functions of catecholamine systems. This article provides an update about plasma levels of catechols and their metabolites and the relevance of those levels to some issues in human health and disease.

[1]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.

[2]  A. Vortmeyer,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes , 2022 .

[3]  E. Eldrup,et al.  Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma , 2001, Scandinavian journal of clinical and laboratory investigation.

[4]  G. Chrousos,et al.  Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. , 2000, The New England journal of medicine.

[5]  M. Esler,et al.  The sympathetic system and hypertension. , 2000, American journal of hypertension.

[6]  D. Goldstein,et al.  Clinical and therapeutic observations in aromatic l-amino acid decarboxylase deficiency , 1999, Neurology.

[7]  D. Goldstein,et al.  Sources and physiological significance of plasma dopamine sulfate. , 1999, The Journal of clinical endocrinology and metabolism.

[8]  D. Goldstein,et al.  Dopamine sulphate: an enigma resolved. , 1999, Clinical and experimental pharmacology & physiology. Supplement.

[9]  J. Pagliaro,et al.  Specific skin lesions occurring in a patient with Hodgkin’s lymphoma , 1999, The Australasian journal of dermatology.

[10]  D. Goldstein,et al.  Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. , 1998, The American journal of physiology.

[11]  J. Lenders,et al.  Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[12]  B. Wallin,et al.  Human muscle sympathetic activity and cardiac catecholamine spillover: no support for augmented sympathetic noradrenaline release by adrenaline co-transmission. , 1998, Clinical science.

[13]  D. Goldstein,et al.  Sympathetic cardioneuropathy in dysautonomias. , 1997, Advances in pharmacology.

[14]  M. Palkovits,et al.  Stressor-specific activation of catecholaminergic systems: implications for stress-related hypothalamic-pituitary-adrenocortical responses. , 1998, Advances in pharmacology.

[15]  D. Goldstein,et al.  Genotype and phenotype in familial dysautonomia. , 1998, Advances in pharmacology.

[16]  É. Mezey,et al.  Substantial production of dopamine in the human gastrointestinal tract. , 1997, The Journal of clinical endocrinology and metabolism.

[17]  B. Bousquet,et al.  Determination of the L-DOPA/L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[18]  D. Goldstein,et al.  Metabolic fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in humans. , 1997, Clinical and experimental hypertension.

[19]  G. Eisenhofer,et al.  Mesenteric Organ Production, Hepatic Metabolism, and Renal Elimination of Norepinephrine and Its Metabolites in Humans , 1996, Journal of neurochemistry.

[20]  A H van Gennip,et al.  Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. , 1996, The Journal of clinical investigation.

[21]  J. Lenders,et al.  Plasma Metanephrines in the Diagnosis of Pheochromocytoma , 1995, Annals of Internal Medicine.

[22]  D. Goldstein,et al.  Monoaminergic Effects of Folinic Acid, l‐DOPA, and 5‐Hydroxytryptophan in Dihydropteridine Reductase Deficiency , 1995, Journal of neurochemistry.

[23]  D. Goldstein,et al.  Production and metabolism of dopamine and norepinephrine in mesenteric organs and liver of swine. , 1995, The American journal of physiology.

[24]  W. Scherbaum,et al.  Plasma catecholamines in patients with Addison's disease , 1995, Clinical endocrinology.

[25]  B. Kingwell,et al.  Aging effects on human sympathetic neuronal function. , 1995, The American journal of physiology.

[26]  C. Sumners,et al.  Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment. , 1995, The American journal of physiology.

[27]  D. Goldstein,et al.  The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. , 1994, Journal of the autonomic nervous system.

[28]  D. Goldstein,et al.  Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans. , 1993, Clinical science.

[29]  D. Goldstein,et al.  Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease , 1993, Annals of neurology.

[30]  D. Goldstein,et al.  Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation. , 1992, The Journal of pharmacology and experimental therapeutics.

[31]  A. Quyyumi,et al.  Sympathetic Nervous Function in Human Heart as Assessed by Cardiac Spillovers of Dihydroxyphenylglycol and Norepinephrine , 1992, Circulation.

[32]  A. Quyyumi,et al.  Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. , 1991, Journal of the autonomic nervous system.

[33]  D. Goldstein,et al.  Glucagon and Clonidine Testing in the Diagnosis of Pheochromocytoma , 1991, Hypertension.

[34]  D. Goldstein,et al.  Dopamine‐β‐hydroxylase deficiency in humans , 1990, Neurology.

[35]  N. Buu,et al.  Origin of dopamine in the rat adrenal cortex. , 1990, The American journal of physiology.

[36]  D. Goldstein,et al.  Patterns of plasma levels of catechols in neurogenic orthostatic hypotension , 1989, Annals of neurology.

[37]  D. Goldstein,et al.  Source and Physiological Significance of Plasma 3,4‐Dihydroxyphenylalanine in the Rat , 1988, Journal of neurochemistry.

[38]  D. Goldstein,et al.  Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. , 1988, The Journal of clinical investigation.

[39]  Y. Oomura,et al.  Effects of hypothalamic stimulation and lesion on adrenal nerve activity. , 1987, The American journal of physiology.

[40]  D. Goldstein,et al.  Neuronal source of plasma dihydroxyphenylalanine. , 1987, The Journal of clinical endocrinology and metabolism.

[41]  D. Goldstein,et al.  DISSOCIATION BETWEEN CORTICOTROPHIN AND CATECHOLAMINE RESPONSES TO ISOPRENALINE IN HUMANS , 1987, Clinical and experimental pharmacology & physiology.

[42]  D. Goldstein,et al.  Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. , 1986, Annals of internal medicine.

[43]  M. Goldberg,et al.  Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. , 1986, The Journal of clinical investigation.

[44]  R. Zimlichman,,et al.  Clonidine suppression testing in essential hypertension. , 1985, Annals of internal medicine.

[45]  D. Charney,et al.  Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. , 1984, Archives of general psychiatry.

[46]  T. Clausen.  Adrenergic control of Na+-K+-homoeostasis. , 2009, Acta medica Scandinavica. Supplementum.

[47]  D. Goldstein,et al.  Circulatory control mechanisms in vasodepressor syncope. , 1982, American heart journal.

[48]  P. Knapp,et al.  Decreased plasma free fatty acids and urinary epinephrine in bronchial asthma. , 1969, The New England journal of medicine.